ESMO 2014 Congress

Panel of Biomarkers May Aid Diagnosis

Madrid—Data from a recent study demonstrated the existence of significant differences in specificity between researchers’ diagnostic panel of markers and prostate-specific antigen (PSA). The researchers reported study findings during a poster session at the ESMO 2014 Congress. The poster was titled Panel of Molecular Markers for Prostate Cancer Diagnosis. Noting that the “most important changes on molecular level affiliated by ... Read More »

New Urinary Biomarker for Prostate Cancer

Madrid—A urinary marker was able to differentiate between benign prostate hyperplasia and prostate cancer in a recent study, according to results presented during a poster session at the ESMO 2014 Congress. The poster was titled Possible Use of Urinary Prostate Proteins Glycosylation Profile as a Diagnostic Biomarker for Prostate Cancer. Screening and early diagnosis of prostate cancer often utilizes serum ... Read More »

Baseline CTC May Identify DN Resistant Patients

Madrid—A recent study sought to examine the biology of cabozantinib based on circulating tumor cell assessment, oncosomes, and tissue studies. Study results were reported during a poster session at the ESMO 2014 Congress in a poster titled Characteristics of de novo Resistance to Androgen Targeting Therapeutics (AR tx) through Circulating Tumor Cells Analysis in Metastatic Castration-Resistant Prostate Cancer Patients. According ... Read More »

Novel Antiandgoren Well Tolerated in MO CRPC High-Risk Patients

Madrid—In high-risk patients with non-metastatic (MO) castration-resistant prostate cancer (CRPC), ARN-509 is well tolerated with robust activity based on durable prostate-specific antigen (PSA) responses and disease control. That was one of the updated results of the ARN-509-001 study conducted by researchers in the United States. Study results were presented during a poster session at the ESMO 2014 Congress. The poster ... Read More »

Bone Scan Index and PFS in Prostate Cancer Patients

Madrid—Increase in bone scan index (BSI) was significantly associated with reduced progression-free survival in a recent study. Study results were presented during a poster session at the ESMO 2014 Congress in a poster title Relationship of Bone Scan Index and Progression-Free Survival Data for Metastatic CRPC Patients Who Received ODM-201. ODM-201 is an androgen receptor inhibitor with high nonclinical and ... Read More »

Dexamethasone versus Prednisone in CRPC

Madrid—Treatment with dexamethasone was superior to treatment with prednisolone in patients with castration-resistant prostate cancer (CRPC), according to results of a phase 2 trial reported during a poster session at the ESMO 2014 Congress. The poster was titled A Randomised Phase II Trial of Dexamethasone versus Prednisolone in Castration Resistant Prostate Cancer. Patients with CRPC are often treated with prednisolone. ... Read More »

Overall Survival Improved with Cabazitaxel plus Prednisone

Madrid—Cabazitaxel plus prednisone (Cbz + P) improved overall survival compared with mitoxantrone (Mtx) plus P in a study utilizing data from the TROPIC trial. That was among the findings of a recent study analyzing the activity of Cbz + P in patients with different numbers of prognostic factors. Analysis results were reported during a poster session at the ESMO 2014 ... Read More »

AR and CYP17A1 Genes May Predict Outcome in CRPC Patients

Madrid—The copy number variations of androgen receptor (AR) and cytochrome P450 17 alpha-hydrolase (CYP17A1) genes are promising markers predicting outcome in patients with castration-resistant prostate cancer (CRPC) in patients treated with abiraterone. That was the primary finding of a study reported in during a poster discussion session at the ESMO 2014 Congress. The poster was titled AR and CYP17A1 Copy ... Read More »

Updated COU-AA-302 Results Show Continued Safety Profile

Madrid—An additional 2 years of follow-up data will be reported at the ESMO 2014 Congress. Charles J. Ryan, MD, and colleagues outlined the pre-specified final analysis (96%) of planned death events), overall survival, and safety outcomes of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients. AA is a prodrug of ... Read More »